Exton, PA, United States
Exton, PA, United States

ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus and hepatitis C virus infections. It was purchased by Shire in 2013, with Shire paying around $4.2 billion for the company in a deal that was finalized in January 2014. ViroPharma was a member of the NASDAQ Biotechnology Index and the S&P 600.The company had strategic relationships with GlaxoSmithKline, Schering-Plough, and Sanofi-Aventis. ViroPharma acquired Lev Pharmaceuticals in a merger in 2008. Wikipedia.


Time filter

Source Type

The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.


Compositions and methods for inhibiting Clostridium associated diseases are disclosed.


The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.


The invention relates to novel crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-(-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.


Compositions and methods for inhibiting Clostridium associated diseases are disclosed.


Methods and compositions are provided for treating diseases implicating alternative pathway complement immune system activation.


A method and composition for treating or preventing antibody-mediated rejection (AMR) of a transplanted organ are provided.


Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.


Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.


The invention relates to novel crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-(-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.

Loading ViroPharma collaborators
Loading ViroPharma collaborators